PT Sarana Meditama Metropolitan (SAME) Fundamentals 2026 — P/E 258.9x, Revenue Analysis | SniperIQ
PT Sarana Meditama Metropolitan (SAME) is a ID-listed Healthcare company in Medical - Care Facilities with a market capitalization of Rp5.12T, trading at Rp298.00 on the JKT. This SniperIQ fundamentals page covers PT Sarana Meditama Metropolitan's valuation (P/E 258.9x, P/B 1.3x), profitability (net margin 1.0%), revenue (Rp1.86T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Sarana Meditama Metropolitan's market cap?
PT Sarana Meditama Metropolitan (SAME) has a market capitalization of approximately Rp5.12T, trading at Rp298.00 on the JKT. Market cap moves with the live share price.
What is PT Sarana Meditama Metropolitan's P/E ratio?
PT Sarana Meditama Metropolitan's trailing twelve-month P/E ratio is 258.9x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Sarana Meditama Metropolitan?
PT Sarana Meditama Metropolitan runs a net profit margin of 1.0%, a gross margin of 26.1%, and an operating margin of 5.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Sarana Meditama Metropolitan generate?
PT Sarana Meditama Metropolitan reported revenue of Rp1.86T for fiscal year 2025, with net income of Rp30.1B and earnings per share (EPS) of 1.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Sarana Meditama Metropolitan pay a dividend?
PT Sarana Meditama Metropolitan does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Sarana Meditama Metropolitan financially healthy?
PT Sarana Meditama Metropolitan carries a debt-to-equity ratio of 0.25x and a current ratio of 0.54x, with a market beta of -0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Sarana Meditama Metropolitan a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Sarana Meditama Metropolitan (SAME) the key facts are: market cap Rp5.12T, P/E 258.9x, revenue Rp1.86T, 52-week range 246-444. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Sarana Meditama Metropolitan's full fundamentals live
Get PT Sarana Meditama Metropolitan's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.